Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good afternoon. This is Bill Maughan. I'm an associate on the SMid-cap Biotech Research Team here at Bank of America. And it's my pleasure to introduce our next presenter, Mark Iwicki, CEO of Kala Pharmaceuticals. Mark?
Thank you very much. And hello, everyone. I'm the CEO of Kala and I want to thank you for joining the call this afternoon. Before getting started, I want to let everyone know that we will make forward-looking statements and all information in this presentation is as of May 13, 2020, and should not be considered current after such date.
So just moving to Slide 3, Kala was formed about 10 years ago based on our AMPPLIFY technology that lets us enhance delivery to target tissues in the eye. We have IP protection for the AMPPLIFY technology and products through at least 2033. Our product that we will spend a lot of time talking about today is EYSUVIS and that is our dry eye product that has the potential to become the preferred first line prescription
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |